3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Neoplasms
4
Lung Neoplasms
4
Advanced Solid Tumors
3
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Thoracic Neoplasms
1
Solid Tumor, Adult
1
Solid Tumor
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Noonan Syndrome
1
Neoplasms by Site
1
Mesothelioma
1
Lung Diseases
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
1
Hereditary Sensory and Autonomic Neuropathies
1
Healthy Participants
1
Carcinoma
1
Bronchial Neoplasms
1
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
1
Advanced Solid Tumor
1
Interventions
Carboplatin
8
Pemetrexed
6
pembrolizumab
5
osimertinib
4
entinostat
3
Paclitaxel
3
Gemcitabine
3
selpercatinib
2
pralsetinib
2
durvalumab
2
Erlotinib Hydrochloride
2
Cisplatin
2
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
necitumumab
1
napabucasin
1
ficlatuzumab
1
exemestane
1
efineptakin alfa
1
cobimetinib
1
ceralasertib
1
camrelizumab
1
atezolizumab
1
alectinib
1
Vinorelbine
1
TNFSF10 protein, human
1
Patient Reported Outcome Measures
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Thoracic Neoplasms
×
sotorasib
×
Clear all
NCT04959981
2023-07-25
HERKULES-2
Erasca, Inc.
Phase 1
Completed
24 enrolled